Genus Lifesciences has announced the re-introduction of Yosprala delayed-release tablets to the US market.
Approved in 2016, Yosprala is a combination of aspirin, an antiplatelet agent, and omeprazole, a proton pump inhibitor (PPI); the combination therapy had been discontinued by Aralez Pharmaceuticals in 2018 based on a business decision and not a safety issue.
Yosprala is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers. According to Genus Lifesciences, the product will be available for $33 for a 30-day supply.
“We are confident that with a unique formulation and new price point, Yosprala will help healthcare practitioners treat patients with secondary cardiovascular and cerebrovascular events with decreased risk of aspirin-associated gastric ulcers,” said Jeffrey Moshal, Chief Executive Officer, Genus Lifesciences, Inc.
Yosprala is available in 2 dosage strengths: aspirin 81mg delayed-release/omeprazole 40mg immediate-release tablets and aspirin 325mg delayed-release/omeprazole 40mg immediate-release tablets. It is not interchangeable with the individual components as the proprietary delivery system is designed to sequentially deliver omeprazole and aspirin.
For more information visit yospralahcp.com.
This article originally appeared on MPR